Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Chemical substance: Tapentadol
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Tapentadol 100mg modified-release capsules
0407020AGAAAKAK
|
Tapentadol | Tapentadol | Central Nervous System | 10 |
|
Tapentadol 150mg modified-release capsules
0407020AGAAALAL
|
Tapentadol | Tapentadol | Central Nervous System | 9 |
|
Tadomon 150mg prolonged-release tablets
0407020AGBDACAE
|
Tadomon | Tapentadol | Central Nervous System | 6 |
|
Tadomon 100mg prolonged-release tablets
0407020AGBDABAD
|
Tadomon | Tapentadol | Central Nervous System | 3 |
|
Tapentadol 200mg modified-release capsules
0407020AGAAAMAM
|
Tapentadol | Tapentadol | Central Nervous System | 3 |
|
Tadomon 200mg prolonged-release tablets
0407020AGBDADAF
|
Tadomon | Tapentadol | Central Nervous System | 1 |
|
Tadomon 25mg prolonged-release tablets
0407020AGBDAFAI
|
Tadomon | Tapentadol | Central Nervous System | 1 |
|
Tapentadol 250mg modified-release capsules
0407020AGAAANAN
|
Tapentadol | Tapentadol | Central Nervous System | 1 |
|
Lupaxis 100mg prolonged-release tablets
0407020AGBEABAD
|
Lupaxis | Tapentadol | Central Nervous System | No data available |
|
Lupaxis 150mg prolonged-release tablets
0407020AGBEACAE
|
Lupaxis | Tapentadol | Central Nervous System | No data available |
|
Lupaxis 200mg prolonged-release tablets
0407020AGBEADAF
|
Lupaxis | Tapentadol | Central Nervous System | No data available |
|
Lupaxis 250mg prolonged-release tablets
0407020AGBEAEAG
|
Lupaxis | Tapentadol | Central Nervous System | No data available |
|
Lupaxis 50mg prolonged-release tablets
0407020AGBEAAAC
|
Lupaxis | Tapentadol | Central Nervous System | No data available |
|
Tadomon 250mg prolonged-release tablets
0407020AGBDAEAG
|
Tadomon | Tapentadol | Central Nervous System | No data available |
|
Tapentadol 100mg tablets
0407020AGAAAPAP
|
Tapentadol | Tapentadol | Central Nervous System | No data available |
|
Tapimio 100mg modified-release capsules
0407020AGBGABAK
|
Tapimio | Tapentadol | Central Nervous System | No data available |
|
Tapimio 150mg modified-release capsules
0407020AGBGACAL
|
Tapimio | Tapentadol | Central Nervous System | No data available |
|
Tapimio 200mg modified-release capsules
0407020AGBGADAM
|
Tapimio | Tapentadol | Central Nervous System | No data available |
|
Tapimio 250mg modified-release capsules
0407020AGBGAEAN
|
Tapimio | Tapentadol | Central Nervous System | No data available |
|
Tapimio 50mg modified-release capsules
0407020AGBGAAAJ
|
Tapimio | Tapentadol | Central Nervous System | No data available |
|
Vecicom 100mg prolonged-release tablets
0407020AGBFABAD
|
Vecicom | Tapentadol | Central Nervous System | No data available |
|
Vecicom 150mg prolonged-release tablets
0407020AGBFACAE
|
Vecicom | Tapentadol | Central Nervous System | No data available |
|
Vecicom 200mg prolonged-release tablets
0407020AGBFADAF
|
Vecicom | Tapentadol | Central Nervous System | No data available |
|
Vecicom 250mg prolonged-release tablets
0407020AGBFAEAG
|
Vecicom | Tapentadol | Central Nervous System | No data available |
|
Vecicom 50mg prolonged-release tablets
0407020AGBFAAAC
|
Vecicom | Tapentadol | Central Nervous System | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.